# US 2022/0033386 A1 · 1, 3-dioxolane derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033386 A1
- Document ID: US20220033386A1
- Status: Published application
- Kind: A1
- Application number: 17/430,884
- Filed: 2020-02-14
- Published: 2022-02-03
- Earliest claimed: 2019-02-15
- Assignees: Tohoku University
- Applicants: Tohoku University
- Inventors: Akira SUGAWARA; Atsushi YOKOYAMA; Susumu SUZUKI; Yoshiharu IWABUCHI; Takayuki DOI
- Web page: https://patentgrep.com/patent/US20220033386A1

## CPC

- A61P 13/00: Drugs for disorders of the urinary system
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides a compound represented by chemical formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.

## Claims

### Claim 1

A compound represented by chemical formula (I):
wherein R1 and R2 are each independently selected from a halogen atom, hydroxy, C1-6 alkyl, and C1-6 alkoxy;
m and n are each independently an integer selected from 0 to 5;
X is —CH2— or —C(═O)—; and
Q is nitrogen-containing 5 to 9-membered heteroaryl attaching via a ring nitrogen atom,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein Q is nitrogen-containing 5-membered heteroaryl or nitrogen-containing 5-membered heteroaryl condensed with a benzene ring, the heteroaryl attaching via a ring nitrogen atom, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein X is —CH2—, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein the compound is represented by chemical formula (Ia):
wherein R1, R2, m, n, and Q are as already defined,
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein n is an integer selected from 0 to 2, and R2 is a halogen atom, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein m is 0, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein Q is 1,2,3-benzotriazol-1-yl, 1,2,4-triazol-1-yl, or imidazolyl-1-yl, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein the compound is selected from:
1-(((2S,4S)-4-((benzyloxy)methyl)-2-phenyl-1,3-dioxolan-2-yl)methyl)-1H-benzo[d][1,2,3]triazole;
1-(((4S)-4-((benzyloxy)methyl)-2-phenyl-1,3-dioxolan-2-yl)methyl)-1H-1,2,4-triazole;
1-(((2S,4S)-4-((benzyloxy)methyl)-2-(4-chlorophenyl)-1,3-dioxolan-2-yl)methyl)-1H-1,2,4-triazole;
1-(((2S,4S)-4-((benzyloxy)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-2-yl)methyl)-1H-1,2,4-triazole;
1-(((2R,4S)-4-((benzyloxy)methyl)-2-(4-chlorophenyl)-1,3-dioxolan-2-yl)methyl)-1H-1,2,4-triazole;
1-(((2S,4S)-4-((benzyloxy)methyl)-2-(4-chlorophenyl)-1,3-dioxolan-2-yl)methyl)-1H-imidazole;
1-(((2S,4S)-4-((benzyloxy)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-2-yl)methyl)-1H-imidazole;
1-(((4S)-4-((benzyloxy)methyl)-2-phenyl-1,3-dioxolan-2-yl)methyl)-1H-imidazole;
1-(((4S)-4-((benzoyloxy)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-2-yl)methyl)-1H-1,2,4-triazole; and
1-(((2R,4S)-4-((benzyloxy)methyl)-2-(4-chlorophenyl)-1,3-dioxolan-2-yl)methyl)-1H-imidazole,
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, for use in treating a disease selected from diabetic nephropathy, glomerular injury, tubular injury, renal injury accompanying advanced age or related to dialysis, nephrosclerosis, nephrotoxicity, renal ischemia, primary vesicoureteral reflux, glomerulosclerosis, IgA-induced nephropathy, and hypertension-induced nephropathy.
